Alistair Macdonald appointed as Operating Partner at GHO Capital
Alistair Macdonald appointed as Operating Partner at GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Alistair Macdonald as Operating Partner.
Alistair has more than two decades of experience in the biopharmaceutical industry, most recently serving as Chief Executive Officer of Syneos Health, a NASDAQ listed Contract Research Organisation (“CRO”). As CEO he more than tripled revenues from 2017 to 2021 leading the company’s transformation from a traditional CRO to a fully integrated biopharmaceutical solutions organization, with contract commercial services.
Alistair previously served as CEO of INC Research, prior to its merger with InVentiv Health to create Syneos Health, driving global expansion and the implementation of innovative technologies, processes and solutions. He has held management positions in the pharmaceutical industry across manufacturing, consultancy, business and corporate development, data management and clinical operations.
In his new role, Alistair will leverage his extensive and successful executive experience of accelerating growth and driving geographic expansion to support value creation within the GHO portfolio, whilst also supporting deal origination across Europe and the US.
The Partners at GHO Capital commented: “We are thrilled to welcome Alistair to the team. His deep industry expertise and long track record of driving operational change across Europe and the US will be invaluable as we scale and internationalize across the portfolio. We look forward to working closely with him as we continue to identify and partner with ambitious management teams to build industry leaders.”
Alistair Macdonald, incoming Operating Partner at GHO, said: “I am hugely excited to have the opportunity to work with GHO. Its portfolio includes some of the most attractive, high growth businesses that we are seeing in the market today. I look forward to working closely with the team to identify new opportunities and accelerate growth across the portfolio, generating long-term sustainable value.”